Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
ABSTRACT Background Spinal muscular atrophy (SMA) is a motor neuron disease caused by mutations in the SMN1 gene. Nusinersen, an antisense oligonucleotide, has been shown to improve motor function in SMA patients. However, concerns regarding its renal safety remain as previous studies have linked si...
Saved in:
Main Authors: | Hüseyin Bahadır Şenol, Gizem Yıldız, Ayşe İpek Polat, Adem Aydın, Ayşe Semra Hız, Alper Soylu, Uluç Yiş |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.70221 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Maximal mouth opening in infants and toddlers with spinal muscular atrophy: a prospective controlled study
by: Jana Zang, et al.
Published: (2025-01-01) -
Quality of life in patients with spinal muscular atrophy in Brazil: patient self-assessment and carer perception
by: Maíra Coelho, et al.
Published: (2025-01-01) -
“…They were just treating her Symptom by Symptom”: maternal experiences of having a child with spinal muscular atrophy in Ghana
by: Esther Doe-Yo Tawiah, et al.
Published: (2025-02-01) -
Variable power functional dilution adjustment of spot urine
by: Thomas Clemens Carmine
Published: (2025-01-01) -
Reduced white matter integrity and disrupted brain network in children with type 2 and 3 spinal muscular atrophy
by: Huirong Nie, et al.
Published: (2025-01-01)